Added to YB: 2026-02-09
Pitch date: 2026-02-06
SOBI.ST [neutral]
Swedish Orphan Biovitrum AB (publ)
+1.26%
current return
Author Info
Nordic Edge provides actionable insights and alpha-generating opportunities in the Nordics. Sign up for the newsletter.
Company Info
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
Market Cap
SEK 123.5B
Pitch Price
SEK 396.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.22
P/E
261.61
EV/Sales
4.74
Sector
Biotechnology
Category
growth
Swedish Orphan Biovitrum (SOBI) Q4-2025 Earnings Review
SOBI.ST (earnings): Strong Q4 with SEK 7,821m revenue (+15% CC), 40% EBITA margin beating guidance. LDD growth + mid-30s margins guided for 2026. Altuvoct EU launch ahead of consensus, Doptelet outperforming. 2026 labeled transition year with elevated OPEX before returning to ~40% margins.
Read full article (2 min)